

International Fetal Medicine and Surgery Society Annual Meeting 2023, September 4-9 Visby – Stockholm, Sweden Scientific Program

Tuesday, 5 September. Venue Donners event.	
8.00 AM	Welcome and Opening Remarks Carmen Mesas Burgos & Peter Lindgren
8.15-10.00 <i>Moderators:</i>	Session 1: Fetal Center Organization/ Risk Stratification / Counseling Charlotta Ingvoldstad Malmgren & Julie Moldenhauer
8.15-8.23	Counseling and multidisciplinary family-centered fetal care: Lessons from advocacy and education Jonathan Castillo
8.23-8.31	Understanding provider perspectives on prenatal decision-making related to congenital anomalies Jessica Fry
8.31-8.39	Innovative delivery of resuscitation guidelines for newborns with congenital anomalies Natalie Rintoul
8.39-8.47	Developing a person-centered care scale for fetal centers Abigail Wilpers
8.47-8.55	The compassion in that room was palpable.": Patients' experiences in U.S. fetal care centers Katie Francis
8.55-9.03	Specialized childbirth classes for pregnant persons with diagnosis of fetal anomalies Bonnie Zapolin
9.03-9.13	Short break
9.13-9.21	When fetal therapies create unpredictable outcomes: ethical considerations in formulating a response Janyne Althaus
9.21-9.29	Supporting patients & families with a fetal spina bifida advanced practice nurse program coordinator Katie Schmidt

A delivery room learning health system

9.29-9.37

	Anna Ades
9.37-9.45	Identification of perinatal mental health and maternal risks among
	BIPOC women carrying fetuses with congenital anomalies
	Joanna C.M. Cole
9.45-9.53	Development of Machine learning algorithms for Antenatal risk
	StratificatiON (MASON) using large datasets from Sweden and Chile
	Mahesh Choolani
9.53-10.01	An innovative data management platform for fetal care: a focus on efficiency
	and validity
	Tom Reynolds
10.01-10.05	Before and after the implementation of an innovative data management
	platform in a fetal center

10.05-10-35 BEVERAGE BREAK Hotel Wisby

Tom Reynolds

10.35-12.00 Session 2: Genetic & Stem cell therapy

Moderators: Mahesh Choolani & Erik Iwarsson

10.35-10.43 The value of exome sequencing in investigating the genetic causes of NIHF - A single-center experience

Xing Wei

10.43-10.51 Repeated fetal hydrops with fetal and neonatal death associated with RYR1 gene mutation

Ricardo Barini

- 10.51-10.59 The Performance of the Expanded Non-invasive Prenatal Testing (NIPT) in High-risk Twin Pregnancy

 Meng Meng
- **10.59-11.07** How to support the profession in prenatal diagnostic counseling in Sweden Charlotta Ingvoldstad Malmgren
- 11.07-11.15 A case of Schuurs-Hoeijmakers syndrome presenting as hydrops fetalis

 Wen-wei Hsu
- 11.15-11.23 Impact of fetal genomic result availability on initial neonatal care of inborn errors of metabolism

 Richard Parad
- 11.23-11.31 Bidirectional traffic of donor mesenchymal stem cells in transamniotic stem cell therapy (TRASCET)

 Kamila Moskowitzova
- 11.31-11.39 Postnatal Fate of Donor Hematopoietic Stem Cells after Syngeneic Transamniotic Stem Cell Therapy

 Kamila Moskowitzova
- **11.39-11.47** Screening protocol for myogenic stem cell differentiation: The first steps *Monalisa Attif Hassan*
- 11.47-11.55 Unravelling heterogeneity of human amniotic fluid stem cells subpopulations

Agnes Klar

11.55-12.05 "I feel good that we did it"- Experiences of parents & stakeholders involved in the BOOSTB4-study Charlotta Ingvoldstad Malmgren

12.05-1.35	LUNCH Hotel Wisby
1.35-3.00	Session 3: Innovative biomolecular therapies
Moderators:	Alan Flake & Joanne Verweij
1.35-1.43	Trials and tribulations of reproducing a retinoic-induced myelomeningocele model for in utero repair Zoe Saenz
1.43-1.51	Transamniotic fetal immunotherapy (TRAFIT) with secretory IgA: A potential novel strategy for the prevention of necrotizing enterocolitis Ashlyn E Whitlock
1.51-1.59	Lipid nanoparticles for in utero base editing of surfactant protein disorders Nicole Kus
1.59-2.07	In utero lipid nanoparticle targeting of the fetal skin for mRNA therapies William Johnston
2.07-2.15	Optimizing prenatal and postnatal therapeutic base editing for hereditary tyrosinemia type 1 Ana Maria Dumitru
2.15-2.22	Characterizing pre-existing maternal immunity as a potential barrier to CRISPR-Cas9 in utero gene editing for metabolic liver diseases William Peranteau
2.23-2.31	Increased efficiency of CRISPR-mediated homology directed repair in the fetus compared to the adult Nicole Kus
2.31-2.39	Prenatal stress modifies maternal circulating small extracellular vesicles and enhances their targeting to the fetoplacental unit Sebastián Illanes
2.39-2.47	Transamniotic delivery of surfactant protein B mRNA in a healthy model Kamila Moskowitzova
2.47-2.55	Vascular dysregulation via NF-kB in fetal growth restriction Timothy M Crombleholme
2.55-3.05	Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease Rohan Palanki
3.05-3.35	BEVERAGE BREAK Hotel Wisby
3.35-5.45 Moderators:	Session 4: Artificial Placenta, Fetal Therapy Ganesh Acharya & George Mychaliska

Keynote: Update on Artificial Placenta

The role of fetal hemoglobin in the artificial placenta

3.35-3.55

3.55-4.03

Alan Flake

	4.00.4.44	George Mychaliska
	4.03-4.11	Characterizing patterns of fetal response to physiologic stress Steven Papastefan
	4.11-4.19	Multiparameter continuous probe monitoring of fetal physiologic
		derangement in fetal surgery Steven Papastefan
	4.19-4.27	Rodent model demonstrates reduced collagen synthesis in uterine scar
		Anisha Apte
	4.27-4.35	The Vortex shunt – short-term feasibility studies in the fetal ovine lower
		urinary tract obstruction and pleural effusion model Enrico Danzer
	4.35-4.45	Short break
	4.45-4.53	The impact of in-utero OSB closure on intra-operative fetal perfusion and
		maternal vital signs
		Sami Backley
	4.53-5.01	Fetoscopic lysis of amniotic band sequence using a 2-port technique: report of four cases
		Sami Backley
	5.01-5.09	Successful open fetal surgery resection of intrapericardial teratoma
		Darrell L. Cass
	5.09-5.17	Stitching of fetal membrane defects in vivo to minimize iPPROM rate Yannick Devaud
	5.17-5.25	Needle fetoscopy: a technique for placement of challenging thoracoamniotic
		and vesicoamniotic shunts
	F 2F F 4F	Steven Papastefan The US Suppose Count of the late of
	5.25-5.45	The US Supreme Court sabotaging prenatal diagnosis and fetal therapy in America
		Mark Evans
Wednesday,	, 6 September	r. Venue Donners event.
	07.00 AM	Fetal Diagnosis & Therapy Editorial Meeting
		(By invitation only. Location: hotel Wisby)
	08.00 AM	Housekeeping Carmen Mesas Burgos & Peter Lindgren
		, 0
	8.10-10.00	Session 5: Thoracic, Airway, Cardiac
	ivloderators:	Anita Moon-Grady & Holly Hedrick
	8.10-8.18	Perinatal airway management in a birth cohort with goiter
		Michael Puricelli
	040030	- Carriary 1 - 1 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -

Congenital lung malformation, Lessons from the last 30 years

8.18-8.26

Reuven Achiron

8.26-8.3	34 Multifocal congenital thoracic lesions Anthony di Natale
8.34-8.4	•
	Erin Perrone
8.42-8.5	Utility of 3-Dimensional modeling in prenatally diagnosed large fetal neck
	mass
	Inna Lobeck
8.50-8.5	0 0 ,
	with fetal hydro: Case seria
	Gongli Chen
8.58-9.0	, , , , , , , , , , , , , , , , , , , ,
	outcome
	Sourav Bose
9.06-9.1	16 Short break
9.16-9.2	24 Detection of fetal hydrothorax associated with mucopolysaccharidosis VII for
3.10 3.2	fetal therapy
	Haruhiko Sago
9.24-9.	
00.	predict postnatal outcome
	Bailey Lyttle
9.32-9.4	• •
	Kristen Gosnell
9.40-9.4	18 Improving prenatal detection of heart disease scalable analysis of six fetal
	cardiac biometrics
	Anita Moon-Grady
9.48-9.5	Direct fetal amiodarone administration for fetal supraventricular tachycardia:
	a case series
	Irvan Adenin
9.56-10	.05 Modulation of the amniotic fluid protein corona on polymeric nanoparticles
	by varying pegylation
	Anna Lynn
10.05-1	0.35 BEVERAGE BREAK Hotel Wisby
10.25.4	2.00 Contract Constant Disabour well allowing Estal Track and Oast size
	2.00 Session 6: Congenital Diaphragmatic Hernia, Fetal Tracheal Occlusion
iviodera	ators: Carmen Mesas Burgos & Philip DeKoninck
10.35-1	1.05 Keynote Innovation: Smart balloon from an engineer's perspective
10.00 1	Nicolas Sananès
11.05-1	1.13 Association between initial mode of ventilation & NICU outcomes for infants
	with severe CDH
	K Taylor Wild

11.13-11.21 Increased alveolar deposits of fibronectin may be responsible for the

pathophysiology of CDH and it may be a potential target for future therapy

	Carolina Pinzon Guzman
11.21-11.29	On-ECMO muscle flap CDH repair associated with fewer bleeding
	complications and improved survival
	Alyssa E Vaughn
11.29-11.37	Bleeding on ECMO: does anticoagulation agent matter in neonates with
	congenital diaphragmatic hernia
	Caroline Credille
11.37-11.45	Prenatal recognition of hepatopulmonary fusion in right-sided CDH for
	successful operative planning
44 45 44 53	Timothy Crombleholme
11.45-11.53	Video review of delivery room resuscitation of neonates with congenital
	diaphragmatic hernia K Taylor Wild
11 53-12 00	Delivery room resuscitation of infants treated with FETO: beyond the balloon
11.33 12.00	K Taylor Wild
12.00-1.15	LUNCH Hotel Wisby
1.15-2.45	Session 7: Fetal tumours and abnormalities, CNS, Abdominal, Urogenital
Moderators:	Shinjiro Hirose & Stephen Emery
1.15-1.23	Revisiting an ovine model for in utero repair of gastroschisis
	Emily Byrd
1.23-1.31	Antenatal risk factors for fetal MP: New insights from a 10-year case-control
	study
	Yan Feng
1.31-1.39	Congenital Extrahepatic Portosystemic Venous Shunt from Fetus to Neonate
	A Need for a New Paradigm Reuven Achiron
1.39-1.47	Obstetric risk profile of serial amnioinfusions for renal anhydramnios
1.55-1.47	Jena Miller
1.47-1.55	Consensus diagnosis, management, and core outcomes set of fetal LUTO: a
1.17 1.55	Delphi procedure
	Hiba Mustafa
1.55-1.03	Transperinal saggittal view for the diagnosis of Posterior Urétral Valves
	Jonathan Rosenblatt
1.03-1.11	The "Halo Sign" of cystic renal dysplasia on fetal MRI
	Judy Estroff
1.11-2.19	Postnatal management and variation in care among neonates in the
	RAFT trial

Amniotic band syndrome with complete extracephalic brain development:

Novel ventriculo-amniotic shunt for treatment of fetal aqueductal stenosis

Ellen Bendel-Stenzel

Stephen P Emery

The math of morphology Christian Macedonia

2.19-2.27

2.27-2.35

2.35-2.43 Neurodevelopmental Outcomes in Complicated Twin Pregnancies: Prospective Observational Study

Asma Khalil

Gregory Heuer

Thursday, 7 September.	Thursday, 7 September. Venue Donners event.		
07.00 AM	IFMSS Executive Board Meeting (By invitation only. Location: hotel Wisby)		
08.00 AM	Housekeeping Carmen Mesas Burgos & Peter Lindgren		
	Session 8: MMC part 1 Peter Conner & Scott Adzick		
8.10-8.18	Characterization of amniotic fluid stem cells obtained from pregnancies with spina bifida aperta Katarzyna Micka		
8.18-8.26	Neonatal outcomes within the Children's Hospitals Neonatal Consortium following fetal MMC surgery Stefanie Riddle		
8.26-8.34	Open spina bifida prenatal repair exclusion criteria in a Chilean reference center Edgardo Corral		
8.34-8.42	Does the psychosocial profile influence the results of open spina bifida surgery? Silvana Echeverria		
8.42-8.50	MCA Doppler around fSB repair: an indirect sign of hindbrain compression and decompression? Ladina Vonzun		
8.50-8.58	Sleep-Disordered Breathing in Neonates with Myelomeningocele: Fetal vs Postnatal Surgery Ellen Bendel-Stenzel		
8.58-9.06	Pain scores after open spina bifida repair in comparison to caesarean sections Nele Strübing		
9.06-9.16	Short break		
9.16-9.24	Maternal obesity in fetal spina bifida repair: is maternal and fetal safety warranted? Julia Zepf		
9.24-9.32	Absence of hindbrain herniation in myelomeningocele/myeloschisis: A closer look		

9.32-9.40	Fetal surgery for MMC: favorable results with expanded indications and refined surgical technique Darrell L. Cass
9.40-9.48	Transient pseudocyst after open fetal myelomeningocele repair Amanda Kalan
9.48-9.56	Differences between Myeloschisis and Myelomeningocele in patients undergoing prenatal repair of OSB Jose Müller
9.56-10.04	Importance of long-term follow-up to the management of myelomeningocele study (MOMS) Katie Schmidt
10.05-10.40	BEVERAGE BREAK Hotel Wisby
10.40-12.00	Session 9: MMC part 2
Moderators:	Martin Meuli & Gregory Heuer
10.40-10.48	Heterotopia and neurodevelopmental outcomes: Prenatal myelomeningocele or myeloschisis
10.48-10.56	Gregory Heuer Neurodevelopmental outcomes of 5-year old patients after open prenatal spina bifida aperta repair Beth Padden
10.56-11.04	Fetoscopic myelomeningocele repair is associated with less fetal bradycardia compared to open repair Steven Papastefan
11.04-11.12	Impact of universal fetal myofascial flap in maternal-fetal surgery for myelomeningocele closure Julie Moldenhauer
11.12-11.20	Fetal spina bifida repair – case one in 2010, case 200 in 2023: The Zurich center's biography from fetal to adult life Martin Meuli
11.20-11.28	Gestational diabetes in women with fetal spina bifida repair - influence of perioperative management Ladina Rueegg
11.28-11.36	Level dependent outcome after fetal spina bifida repair Ueli Moehrlen
11.36-11.44	Measuring physical functioning in the MOMS3 Fetal Surgery Study: An interprofessional collaboration Janet Jackson-Coty
11.44-11.52	Global folate fortification efforts Gregory Heuer
11 52-12 00	Perinatal mood and anxiety in women undergoing onen maternal-fetal

surgery for myelomeningocele Nina Paidas Teefey

12.00-1.30	LUNCH Hotel Wisby
1.30-3.00	Session 10: Multiple Pregnancies
	Sverker Ek & Mark Johnson
1.30-1.38	Association of fetal growth restriction and stillbirth in twin compared to singleton pregnancies Asma Khalil
1.38-1.46	Prediction of stillbirth and adverse perinatal outcomes in dichorionic twin pregnancies Asma Khalil
1.46-1.54	Perinatal outcomes in twin reversed arterial perfusion sequence with early or late intervention Luming Sun
1.54-2.02	Management of twin-reversed arterial perfusion sequence: a systematic review and meta-analysis Inna Lobeck
2.02-2.10	Consensus protocol for the management of early and late twin-twin transfusion syndrome: Delphi study Asma Khalil
2.10-2.18	Machine-Learning prediction of gestational hypertension and preeclampsia in twin pregnancies Hiba J. Mustafa
2.18-2.26	Machine-Learning early pregnancy risk prediction model for gestational diabetes in twin pregnancies Hiba J. Mustafa
2.26-2.34	Modified selective fetal reduction by radiofrequency ablation in twin-twin transfusion syndrome Zhiyang Hu
2.34-2.42	Early unfavorable outcomes of umbilical cord occlusion for complicated monochorionic twins Tuangsit Wataganara
2.42-2.50	Twin Reversed Arterial Perfusion Sequence Indonesia Single Center Experiences in Fetal Interventions Dudy Aldiansyah
3.00-3.30	BEVERAGE BREAK Hotel Wisby
3.30-5.45 Moderators:	Session 11: TTTS, Intra Uterine Transfusions Ken Moise & Enrico Lopriore
3.30-3.38	Placental panorama picture generated by a magnetically assisted robotic surgery system for the treatment of twin-to-twintransfusion syndrome Ueli Moehrlen
3.38-3.46	Stitch it up! Trans-amniotic membrane closure of fetoscopic site in laser photocoagulation for TTTS

Foong Yen Lim

3.46-3.54	Long-term outcomes in children treated with laser therapy for TTTS in a U.S.
	cohort
	Eric Bergh
3.54-4.02	Amniotic fluid biomarkers of fetal stress response to cardiac dysfunction in
	TTTS
	Steven Papastefan
4.02-4.10	The impact of cannula diameter on preterm prelabor rupture of membranes
	after laser surgery
	Anouk van der Schot
4.10-4.18	M-sign in middle cerebral artery Doppler in twin-to-twin transfusion
	syndrome
	Ladina Rueegg
4.18-4.26	Rapidly progressive TTTS despite fortnightly US surveillance
	Greg Ryan
4.26-4.34	Changes in hematocrit following uncomplicated laser ablation for TTTS
	Martin Walker
4.34-4.44	Short break
4.34-4.44	Short break
4.44.4.52	Perinatal survival following intrauterine transfusion for red cell
4.44.4.52	Perinatal survival following intrauterine transfusion for red cell alloimmunized pregnancies
4.44.4.52	Perinatal survival following intrauterine transfusion for red cell alloimmunized pregnancies Alireza Shamshirsaz
4.44.4.52 4.52-5.00	alloimmunized pregnancies
	alloimmunized pregnancies Alireza Shamshirsaz
	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine
	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion
4.52-5.00	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou
4.52-5.00	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the
4.52-5.00	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn
4.52-5.00 5.00-5.08	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA
4.52-5.00 5.00-5.08	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr
4.52-5.00 5.00-5.08 5.08-5.16	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe HDFN
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26 5.26-5.34	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe HDFN Dick Oepkes
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe HDFN Dick Oepkes Postnatal management and outcome in hemolytic disease of the fetus and
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26 5.26-5.34	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe HDFN Dick Oepkes Postnatal management and outcome in hemolytic disease of the fetus and newborn (HDFN): results from an international registry (Dionysus study)
4.52-5.00 5.00-5.08 5.08-5.16 5.16-5.26 5.26-5.34	alloimmunized pregnancies Alireza Shamshirsaz Atrioventricular plane displacement in fetuses before and after intrauterine blood transfusion Aikaterini Zamprakou Utility of fetal antigen testing in the management of hemolytic disease of the fetus and newborn TBA Clinical outcomes of standard of care for early-onset severe HDFN Dick Oepkes Nipocalimab in pregnancies at high risk for early-onset severe HDFN Kenneth J. Moise Jr Phase 3 study design of nipocalimab in pregnancies at risk for severe HDFN Dick Oepkes Postnatal management and outcome in hemolytic disease of the fetus and

Friday, 8 September. Stockholm Theater Ship 1.30-4 pm

2.45-4.00

Lunch 12 – 1.30 PM		
1.30-2.30 Moderators	Session 12: Special lectures and business meeting s: Peter Lindgren & Greg Ryan	
1.30-1.40	Growth in children with Osteogenesis Imperfecta type III after prenatal treatment with fetal mesenchymal stem cells Magnus Westgren	
1.40-1.50	The contribution of genetics to Cerebral Palsy Mark Evans	
1.50-2.00	IFMSS at 40: You heard it here first Francois I. Luks	
2.00-2.10	What happens in Cabo shouldn't stay in Cabo: our lessons learned Amy B Powne	
2.10-2.40	Behind the scenes at the Nobel festivities Tobias Degsell	

Business meeting and meeting closing